REV1 inhibition elicits differential response to cancer therapy
Crompton, Andrew
Crompton, Andrew
Citations
Altmetric:
License
0
License
DOI
Abstract
Developing methods to target resistance mechanisms is an important avenue in cancer research. A DNA damage tolerance pathway, translesion synthesis (TLS), contributes to resistance through bypassing DNA damage caused by genotoxic therapies. TLS inhibition is an emerging area of research, and it has been shown that REV1 inhibition, a TLS polymerase, sensitizes cancer cells to cisplatin treatment. In this study, we address whether REV1 inhibition similarly sensitizes cancer cells to radiation therapy. We found that REV1 inhibition confers radioresistance and triggers autophagy. These findings present REV1 as a modulator of response to cancer therapy and warrants further investigation
Description
Undergraduate
Date
2023-01-01